Digital Therapeutic for Schizophrenia
A new digital therapeutic, CT-155, has shown promise in reducing negative symptoms of schizophrenia.
Developed by Boehringer Ingelheim and Click Therapeutics, CT-155 is a smartphone app that uses adaptive goal-setting techniques to deliver psychosocial interventions.
- Phase 3 trial demonstrated reduction in negative symptoms of schizophrenia.
- Exhibited good tolerability and no significant adverse events when used with antipsychotic treatment.
CT-155 is the first experimental prescription digital therapy to demonstrate such results.
An estimated 24 million people worldwide have schizophrenia, according to the World Health Organization, characterized by persistent delusions and hallucinations.
Author's summary: Digital therapeutic CT-155 reduces schizophrenia symptoms.